Patent Ductus Arteriosus News and Research

RSS

Patent ductus arteriosus (PDA), one of the more common cardiac defects present at birth, is the persistence of an opening between the pulmonary artery and aorta.

Study assesses whether early targeted treatment of patent ductus arteriosus improves outcomes in extreme preterm babies

A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm babies.

22 Apr 2022

Johns Hopkins Children’s Center doctors save a newborn baby with congenital diaphragmatic hernia

Sarah Gonzalez was just 13 weeks pregnant in 2018 when she received "terrifying" news during a routine ultrasound.

19 Apr 2022

Early PDA closure may reduce adverse outcomes in premature babies

Extremely low birth weight (ELBW) infants with moderate to large patent ductus arteriosus (PDA) may benefit from transcatheter PDA closure (TCPC) in the first four weeks of life, according to research published by Le Bonheur Cardiologist Ranjit Philip, MD, and Medical Director of Interventional Cardiac Imaging and Interventional Catheterization Laboratory Shyam Sathanandam, MD.

26 Feb 2021

Experts define TRAF7 syndrome-associated phenotype spectrum

An international multicentre study describes a rare disease characterized by a series of recognizable facial features, cardiac defects and intellectual disability, which they propose to name as TRAF7 syndrome -according to the name of the gen that causes this pathology.

19 May 2020

Research shows programmed postnatal transition in newborn’s heart

In the fetus, the blood vessel known as the ductus arteriosus or ductus Botalli bypasses blood from the lung artery to the aorta.

13 Jun 2018

Researchers compare shunts and stents to maintain blood flow in infants with heart disease

Infants with various forms of congenital heart disease require a stable source of blood flow to their lungs in order to survive until a more definitive operation can be performed. In a recent study, pediatric researchers compared two methods to provide that flow: a shunt to reroute blood and an implanted stent to maintain an open path for blood flow.

21 Nov 2017

New report highlights trends in heart disease care in the U.S.

Over 93 percent of heart attack patients are receiving stents within the guideline-recommended threshold of 90 minutes after arriving at the hospital, with the median time to stenting only 59 minutes, according to a broad report on trends in heart disease care from the American College of Cardiology's National Cardiovascular Data Registry published in the Journal of the American College of Cardiology.

18 Jan 2017

Study reveals benefit of early screening for vascular disorder patent ductus arteriosus among preterm infants

Among extremely preterm infants, early screening for the vascular disorder patent ductus arteriosus before day 3 of life was associated with a lower risk of in-hospital death and pulmonary hemorrhage, but not with differences in other severe complications, according to a study in the June 23/30 issue of JAMA.

24 Jun 2015

Caution on COX inhibitor use in preterm infants

Very-low-birthweight preterm infants with thrombocytopenia treated with cyclooxygenase inhibitors are at an increased risk for intracerebral hemorrhage, particularly if they have decreased platelet levels, research shows.

5 Feb 2013

Low platelet count not associated with patent ductus arteriosus

Thrombocytopenia in the first 24 hours after birth is not linked to patent ductus arteriosus in low birthweight infants, research shows.

13 Aug 2012

Medunik Canada signs exclusive distribution agreement with Orphan Europe

Medunik Canada, is an orphan drug company dedicated to helping Canadians with rare diseases access therapies currently unavailable in Canada. Medunik Canada is proud to announce that it has signed an exclusive distribution agreement with Orphan Europe Recordati Group.

5 Jul 2012

UTHealth, PLx Pharma to test phosphatidylcholine-enriched version of indomethacin in PDA model

PLx Pharma Inc, a Houston-based pharmaceutical company developing a medical discovery made at The University of Texas Health Science Center at Houston (UTHealth) Medical School, has been awarded $565,449 for the first year of a potential two-year $1,118,398 grant to conduct research designed to enhance a treatment for premature babies with a common congenital heart defect.

29 Mar 2012

Pediatric physicians present 12 research abstracts, posters at Cardiology 2011

Pediatric cardiology researchers and clinicians gather this week in Scottsdale, Ariz. for Cardiology 2011, the 15th Annual Update on Pediatric and Congenital Cardiovascular Disease, sponsored by The Children's Hospital of Philadelphia. Original research from more than 30 cardiac programs in the U.S. and abroad is being presented throughout the meeting.

7 Feb 2011

Lundbeck voluntarily recalls two lots of NeoProfen Injection

Lundbeck Inc. has voluntarily recalled two lots of NeoProfen® (ibuprofen lysine) Injection that failed to meet a visible particulate quality requirement. These two lots are the only lots currently available to prescribers and therefore the recall will result in a temporary drug shortage. This voluntary recall is the result of the company's inspections of the two product lots of NeoProfen.

31 Jul 2010

NIH awards PLx Pharma multiple grants for development of GI safer NSAIDs

PLx Pharma, a pharmaceutical company developing safer formulations of proven non-steroidal anti-inflammatory drugs (NSAIDs), today announced that it has been awarded multiple grants from the National Institutes of Health (NIH) totaling approximately $2,000,000. This funding has been awarded to support further advancement of a range of products currently under development by PLx.

12 May 2010

FDA approves APP Pharmaceuticals' Indomethacin for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Indomethacin for Injection. Indomethacin is therapeutically equivalent to the reference-listed drug INDOCIN® I.V., by Lundbeck, Inc.

23 Mar 2010

Bedford Laboratories launches Indomethacin for Injection

Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., a provider of select specialty injectables, is pleased to announce the addition of Indomethacin for Injection to its existing product line. This product is AP rated and is equivalent to Indocin® by Lundbeck, Inc. Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective.

17 Feb 2010

Patent Ductus Arteriosus News and Research

Further Reading